Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
Angus DC, Linde-Zwirbie WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Critical Care Medicine. 2003;31:1–11.
This article assesses the cost-effectiveness of drotrecogin alfa (activated) and evaluates it against the backdrop of healthcare strategies at large.
|
This item has not yet been rated
|
 |
View article abstract
|
